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Parkinson’s disease (PD) is a neurodegenerative disorder that is common in older individuals. 
PD patients have an increased risk of fractures compared to the general population, perhaps 
due to multiple falls. However, the fracture risk has not been fully assessed. To assess the 
impact of PD on the risk of hip and non-vertebral fractures, we conducted a systematic review 
and meta-analysis. 
Comprehensive searches of three key bibliographic databases were conducted to identify 
reviews and primary studies relating to the risk of fractures in patients with PD. Search terms 
included all relevant terms for Parkinson’s disease and for fractures. We selected observational 
studies with data on the risk of fractures in adults with PD compared to controls without the 
diagnosis. Study quality was assessed using the Newcastle Ottawa Scale. The random-effects 
model was used to pool the results. 
Eighteen studies were included in the review. Seventeen independent studies (14 cohort and 3 
case-control studies) were included in the hip fracture analysis. Nine studies (all cohorts, no 
case-control studies) were included in the non-vertebral fracture analysis. Study quality was 
judged to be moderate to good. Overall, PD patients had an increased risk for both hip fractures 
(2.40, 95% CI 2.04 to 2.82) and non-vertebral fractures (1.80, 95% CI 1.60 to 2.01) compared 
to controls. The relative risk for hip fractures was higher in men (2.93, 95% CI 2.05 to 4.18) 
than in women (1.81, 95% CI 1.61 to 2.04). There were no effects of the study design, 
geographical region, or criteria for diagnosing Parkinson’s disease on these estimates of 
fracture risk. 
There is an increase in the risk of hip and non-vertebral fractures in patients with Parkinson’s 
disease and we recommend a re-evaluation of the clinical guidelines on bone health in patients 
with PD to address this.  
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Highlights 
• There is a positive association between Parkinson’s disease and the risk of  hip fractures 
(2.40, 95% CI 2.04 to 2.82)  
• There is a positive association between Parkinson’s disease and the risk of non-
vertebral fractures (1.80, 95% CI 1.60 to 2.01) 




Parkinson’s disease is a common neurodegenerative disease with a lifetime risk of 2% for men 
and 1.3% for women in the USA, taking into account competing risks of death (1). It mainly 
affects individuals after the age of 50, and the incidence increases with age. A study of seven 
European community surveys of independently living and institutionalized elderly subjects 65 
years of age or older found an overall prevalence of 0.6% in adults aged 65 to 69 years, 
increasing to 2.6% for those 85 to 89 years (2). The incidence stabilises after the age of 80, 
probably because of underdiagnosis (3).  
Parkinson’s disease patients have more than a threefold increase risk in falls compared to age- 
and gender-matched controls (4). PD has also been linked to higher risk of osteoporosis and 
lower bone mineral density (BMD) levels (5). These factors contribute to an increased risk of 
fractures in patients with PD, which has been observed in several studies, with hip fracture 
being the most common site (5-7). 
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Despite the numerous individual studies published on the risk of fractures, the relationship 
between PD and the risk of hip and non-vertebral fractures has not been systematically assessed. 
Previous meta-analyses have focused on the general risk of fractures (5, 6). A recently 
published systematic review on the risk of hip fractures excluded studies that only reported 
event rates without a summary statistic and it excluded studies that included patients with 
parkinsonism, which may have affected the pooled risk estimate reported (8). Parkinsonism is 
an atypical form of Parkinson’s disease that makes up about 10% of cases and may progress 
more rapidly than Parkinson’s disease and is less responsive to the usual treatment, levodopa.  
This review aims to address the question “what is the risk of hip and non-vertebral fractures in 
adult patients with Parkinson’s disease compared to those without Parkinson’s disease?” 
through a systematic review and meta-analysis. It also seeks address the limitations of previous 
reviews by including a wider pool of studies and to assess whether the risk differs in patients 
according to age, sex, study quality and presence of dementia. We chose these two 
classifications of fracture as they are well captured in epidemiological studies, in contrast to 
vertebral fractures, which require serial radiographs for their accurate identification. It is of 
particular importance to assess the risk of non-vertebral fractures as this is a major endpoint in 
clinical trials of fractures. 
 
Materials and methods 
Protocol and registration 
This systematic review was conducted following key principles outlined in the Cochrane 
Handbook (9) and in the Centre for Reviews and Dissemination Handbook (10).  It  has been 
reported in accordance with the PRISMA statement (11). The protocol for this review was 
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registered on the PROSPERO database (https://www.crd.york.ac.uk/prospero/), record number 
CRD42018094911.  
Information sources and search strategy 
Systematic searches of bibliographic databases were conducted to identify published 
systematic reviews and update these with more recently published primary studies.  An initial 
full search was conducted in MEDLINE and Embase and updated on 29th March 2019 
(MEDLINE only) using free text and thesaurus terms for fractures, Parkinson’s disease and 
study design (Supplemental data 1).  The reference lists of key existing reviews (5, 12) were 
searched and experts in the field consulted for additional primary studies. 
Study selection 
Retrieved records were uploaded into Endnote and duplicate records were removed. For the 
study of previous systematic reviews, one reviewer assessed records against the inclusion 
criteria. A second reviewer independently sifted a 10% sample and the Kappa statistic for 
agreement was calculated. For the review of primary studies, one reviewer conducted the title 
and abstract sift, and a second reviewer  independently sifted a 10% sample. The Kappa statistic 
for agreement was calculated. The full text sift was conducted independently by two reviewers 
and disagreements resolved through discussion, or involvement of a third reviewer.  
Systematic reviews and primary studies were eligible for inclusion where they met the 
following criteria: population included adults aged 18 years and above with a diagnosis of 
Parkinson’s disease (identification of patients through medication records was an acceptable 
form of diagnosis); included a comparison group of patients without Parkinson’s disease; 
reported outcomes of hip and/or non-vertebral fractures; had an observational design (primary 
study review) or were a systematic review of studies with an observational design (review of 
systematic reviews). Studies were excluded if: the Parkinson’s disease definition/diagnosis was 
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unclear; data was not reported separately for Parkinson’s disease patients; the diagnosis was 
made after the fracture event or where the sequence was unclear; the comparator group was not 
clearly defined; data was only available on vertebral fractures or there was no way to exclude 
the data from vertebral fractures; fracture risk was based on an algorithm or risk tool; outcome 
data was unclear, missing or incomplete; the study was not in English; or was a narrative review, 
letter, editorial, commentary, conference abstract, animal or biological study.  
When two or more studies were identified that included or potentially included the same 
patients (based on recruitment location, database name (where provided) and years of 
recruitment), and where they reported data relating to the same fracture sites, the study with 
the largest sample size was used, or which reported protocol-defined subgroup analyses (e.g. 
by fracture site, age, sex etc). Where both a cohort study or a case-control study were available, 
the cohort study was selected for inclusion in the review.  
Studies included in the selected systematic review (6) were further assessed based on the 
current inclusion and exclusion criteria and the data from the selected studies was fully 
extracted as described below. 
Data extraction 
A standardized data extraction form was developed and agreed with the clinical team. Data 
from all the studies selected, were extracted by one reviewer and checked by another. 
Disagreements were resolved through discussion. A blank sample of the data extraction form 
is provided in Supplemental material 2.  
Quality assessment 
The quality of the existing systematic review was assessed using AMSTAR (13) by one 
reviewer and checked by a second. The quality of primary studies was assessed using the 
Newcastle Ottawa Scale (NOS) (14) for cohort and case-control studies by one reviewer and 
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checked by a second; disagreements were resolved through discussion. A maximum score of 9 
stars could be assigned to a study. The scoring guidelines are provided in Supplemental 
material 3.  
Narrative synthesis 
A narrative synthesis was conducted, including tabulation of study characteristics, and a 
description of the available data. Subgroups were defined a-priori and included gender, study 
location (continent), type of effect size reported (relative risk, hazard ratio, odds ratio, or 
incidence risk ratio), type of study design (cohort or case-control). Parkinson’s disease is a 
disorder that requires clinical diagnosis and there is no available imaging or laboratory method 
to confirm the diagnosis; previous meta-analyses excluded studies with Parkinsonism. For 
these reasons, it was decided to subgroup the studies further in three different ways wherever 
possible: clear definition of clinical criteria used for the diagnosis of PD, diagnosis used in the 
study (Parkinson’s disease or Parkinsonism), method of PD diagnosis (self-report only or other).  
Data analysis 
Hip, vertebral and non-vertebral fractures are the groupings usually used in clinical trials of 
drugs to prevent fractures. However, the group of vertebral fractures is captured poorly in 
observational studies, as it requires regular spinal radiographs to identify morphometric 
fractures. Therefore, this analysis included only hip and non-vertebral fractures. The available 
measures of effect size (ES) and their 95% confidence intervals (CI) were extracted from the 
studies. These included relative risk (RR), hazard ratio (HR), odds ratio (OR) and incidence 
risk ratio (IRR). If multiple effect sizes were reported from one study because of different 
adjustments, the one with the fewer adjustments was used for the meta-analysis, as many 
adjustments would increase the heterogeneity between studies. For studies that did not report 
an effect size, this was calculated using the raw data for fractures reported in the study (15, 16). 
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In these cases, the relative risk, its standard error and 95% confidence interval were calculated 
(17). In the case of studies that reported zero fractures in one subgroup, this number was 
substituted with 0.5 to allow further calculations (18, 19).  
For studies that reported separate risks for hip and femur fracture, a pooled effect size was used 
in the main analysis (20).  For the non-vertebral fracture analysis, one effect size per study was 
used. Therefore, if a study reported several effect sizes according to different fracture sites, 
then these effect sizes were pooled to get an overall estimate (15, 16, 20-25). Effect sizes on 
skull fractures were excluded. The non-vertebral fracture analysis only included studies that 
reported the risk of more than one non-vertebral site or reported the overall risk of “non-spine” 
fractures. Studies where the only outcome was hip fracture were not included in the non-
vertebral analysis.  
A meta-analysis of the natural logarithms of the effect sizes and their confidence intervals was 
performed and presented using forest plots. The random-effects model was used to pool the 
results (26). If a study only reported separate estimates by gender, and an overall estimate was 
not given, then the separate estimates where used for the meta-analysis (27, 28).  
Statistical heterogeneity was assessed using Cochran’s Q test and the 2 statistic (29). Since the 
chi-squared test has low power, the p value of 0.10, was used to determine statistical 
significance. Where the pooled effect had considerable heterogeneity, further analyses were 
conducted to identify possible reasons for the observed heterogeneity. A leave-one-out 
sensitivity analysis, was used to check how each individual study affected the overall estimate 
and a meta-regression analysis was performed to investigate the extent to which heterogeneity 
could be related to one or more characteristics of the studies.  
Subgroup analyses were carried out according to predefined groups. If there was no overlap of 
the confidence intervals, then we concluded that there was statistical significance between the 
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subgroups (9, 30). A sensitivity analysis was performed limiting the pooled studies to those 
having a high-quality assessment score according to the Newcastle Ottawa scale (≥7).  
Publication bias was assessed through visual inspection of a funnel plot (31). A formal 
statistical assessment, was performed using Egger’s test (32). When statistically significant 
bias was identified, the trim-and-fill method was used to adjust for that (33, 34). Testing for 
publication bias was only performed when there were more than 10 studies in the analysis (32). 




The review of systematic reviews database searches identified 452 unique records. Based on 
the title or the abstract, 388 records were excluded. From the remaining 64 records, one 
systematic review met the inclusion criteria for the review (6). The kappa statistic for 
agreement between reviewers was 1.00 (95% CI 1.00, 1.00) indicating very good agreement. 
The systematic review of primary studies database searches identified 355 records (four from 
the update search in March 2019), of which 233 were unique. Hand searching of existing 
reviews and contact with experts in the field retrieved a further 28 records. In total, 261 unique 
records were considered for inclusion in the review. Of these, 180 were excluded based on the 
title or abstract, and the full text of 81 records was retrieved for assessment against the inclusion 
criteria. A further 63 were excluded after consulting the full text (full list with reasons provided 
in Supplemental material 4), leaving a total of 18 (15, 16, 20-25, 27, 28, 35-42) primary studies 
that met the inclusion criteria and were included in the review. Of these, 17 were included in 
the meta-analysis for hip fracture (15, 16, 20-25, 27, 28, 35-38, 40-42) and 9 were included in 
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the meta-analysis for non-vertebral fractures (15, 16, 20-25, 39). The study statistic for 
agreement between reviewers was 0.697 (95% CI 0.297, 1.000) , indicating good agreement. 
The flow chart for the selection is shown in Figure 1.  
 




Table 1  summarises the main characteristics of the 18 studies included in the analyses. In total, 
three studies had a case-control design (28, 37, 40) and the rest were cohort studies. The study 
population ranged from 52 to 1,276,891 participants, with a total of 2,335,361. Average follow-
up varied between 1 and 14 years. All the studies started patient recruitment after 1975.  
Three studies included males only (38-40), one study consisted of females only (25). Only four 
studies reported ethnicity, with the majority of the participants being Caucasian. Only a few 
studies reported the prevalence of dementia, but none reported the risk of fractures according 
to dementia status, which was one of the planned subgroup analyses.   
Three studies reported data on bone mineral density (BMD) measurements according to PD 
status, with two of them showing significantly lower BMD results in PD patients compared to 
controls [0.876 g/cm2 vs 0.958 g/cm2 respectively, p<0.001 and 0.68± 0.14 vs 0.74 ±0.13 g/cm2 
respectively, p 0.005 (25, 39)]. One cohort showed no statistical difference in BMD (16). There 
was one cohort study  that reported BMD measurements according to hip fracture status 
[femoral neck BMD (g/cm2): no hip fracture 0.79 ± 0.13 g/cm2, hip fracture 0.67 ± 0.11 g/cm2 
(p<0.001)] (38).  
In terms of diagnosis, three studies evaluated people with parkinsonism (23, 28, 36), while the 
others evaluated people with Parkinson’s disease (15, 16, 20-22, 24, 25, 27, 35, 37-42). Three 
studies gave the criteria used for the diagnosis of PD. Only two studies used self-report alone 
as a method of diagnosis (28, 40). One study identified patients with idiopathic PD using 
dispensed medication and reported two models; model I (‘possible’ idiopathic PD patients) and 








Country Study population Diagnosis for PD/ Parkinsonism Study size, 
Number of PD patients,  
Number of incident 
fractures 





Cohort New Zealand InterRAI-HC geriatric assessment record PD; Assessment, including observations, 
interviews with the individual and their family 




≥65 61.5 Median 13.9 m 
An (2017) 
(36) 
Cohort South Korea National Health Insurance Service (NHIS) 
National Sample Cohort (NSC) 
Parkinsonism; Insurance registry  15498 
2583 
325 






Netherlands Dutch PHARMO Record Linkage System 
(RLS)  
Institute for Drug Outcome Research 





≥18 73 Cases: 5.8 y 
Controls: 5.7 y 
Benzinger 
(2014) (27) 
Cohort Germany Allgemeine Ortskrankenkasse Bayern 
(AOK Bavaria) 
PD; Registry of discharges and medication 872779 
12391 
34147 
≥65 62.7 cases 
63.3 controls 
Cases: 4.50y 
(2.47 to 4.50) 
Controls: 4.50y 
(4.50 to 4.50) 
Cauley 
(2016) (38) 
Cohort USA The Osteoporotic Fractures in Men 
(MrOS) Study 
PD; Self-report, interview or examination 5876 
48 
178 
≥65 0 8.6 y 
Fink (2008) 
(39) 
Cohort USA The Osteoporotic Fractures in Men 
(MrOS) Study 
PD; Self-report, interview or examination 5937 
46 
NR 
≥65 0 Cases: 4.1y (0-6 
to 6), Controls: 





PD register of the Movement Disorder 
Clinic at Chesterfield and North 
Derbyshire Royal Hospital 
PD; Outpatient department registry, diagnosed 
by a consultant Care of the Elderly physician, 
specialised in movement disorders, using the 
United Kingdom Parkinson’s Disease Society 









USA 34 Hospitals in Philadelphia 
(Pennsylvania) and Kaiser Permanente 








≥45 0 NR 
Huang 
(2015) (21) 
Cohort Taiwan Taiwan National Health Insurance 
Research Database 
PD; Insurance registry: At least 3 outpatient 
visits or inpatient medical services with 




≥40 44.6 NR 
Jørgensen 
(2014) (22) 
Cohort Denmark Danish Civil registration System, Danish 
National Patient registry, Danish National 
Prescription registry, Income Statistics 
registry 
PD; Registries of admissions and prescriptions 1276891 
NR 
NR  
≥65 58.5 NR 
Kalilani 
(2016) (20) 
Cohort USA Truven Health MarketScan1 Commercial 
Claims (CCMC) and the Truven Health 
MarketScan Medicare Supplemental and 
Coordination of Benefits (Medicare 
Supplemental; MDCR) insurance 
databases 
PD; Insurance registry, 
























Asian Osteoporosis Study (AOS)  Parkinsonism; Self-reported questionnaire 2338 
NR 
1176 
≥50 61.2 NR 
Lorefält 
(2007) (16) 
Cohort Sweden Linkçping cohort PD; Outpatient departments, using UK 





≥60  65.4 1 y 
Melton 
(2006) (23) 
Cohort USA Rochester Epidemiology Project Parkinsonism; Medical record, according to 
following criteria: at least two of four cardinal 
signs (resting tremor, bradykinesia, rigidity, or 
impaired postural reflexes) with all three of the 
following: (1) no secondary cause; (2) no 
documentation of unresponsive- ness to 
levodopa treatment (applicable only to treated 
patients); and (3) no prominent or early (within 
1 year of onset) signs of more extensive 
nervous system involvement (e.g., dementia or 










UK General Practice Research Database 
(GPRD) 
PD; Diagnosis in medical records plus two 




≥40 42 4 y 
Schneider 
(2008) (25) 
Cohort USA Study of osteoporotic fractures (SOF) PD; Questionnaire, physical examination, 




≥65 100 8 y non-spine, 
non-hip  
9 y hip cohort 
Wiklund 
(2016) (42) 
Cohort Sweden Umeå 85+/ Gerontological Regional 
Database (GERDA) 





≥85 65.8 Mean 2.7 y (1–
1827 days) 
Table 1: Summary of included studies examining the association between Parkinson’s disease and the risk of hip and non-vertebral fractures 
Y: years; m: months; NR: not reported
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Quality assessment 
The selected systematic review by Tan et al (6) was found to be of good quality, scoring well 
on eight out of eleven items on the AMSTAR checklist. The scores are provided in 
Supplemental material 5. The review scored poorly for not reporting a priori design, excluding 
conference abstracts, and not providing a full list of excluded studies. However, the review also 
addressed the question of risk of fractures in patients with PD, and was conducted to a high 
standard with duplicate study selection, comprehensive literature searches, quality assessment 
and appropriate methods of analysis with no conflicts of interest.  
A summary of the judgement of the quality of the included primary studies is provided in Table 
2 (cohort studies) and Table 3 (case-control studies). Justifications for the scores given are 
provided in Supplementary data 5. Overall, cohort studies were of good quality, with all scoring 
more than or equal to 7 out of 9 stars. Most studies scored poorly for the item “adequacy of 
follow-up”; this was largely due to no information being given in the study report.   
Case-control studies (n=3) generally scored less well than cohort studies, with no study scoring 
7 or more out of 9 possible stars. All studies failed to report whether cases were consecutive 
and failed to present data that would allow a judgement to be made about the representativeness 
of the recruited population. All studies scored poorly for their definition of controls, because 
cases were defined as first instance of hip fracture (i.e. patients with previous hip fracture were 


























Abey- Nesbit, 2019 (35) * * * * ** * * * 9 
An, 2017 (36) - * * * ** * - * 7 
Benzinger, 2014 (27) * * * * ** * * - 8 
Cauley 2016(38) - * * * ** * * * 8 
Fink, 2007 (39) - * * * ** * * * 8 
Genever, 2005 (15) * - * * ** * * - 7 
Huang, 2015 (21) - * * * ** * * * 8 
Jørgensen, 2014 (22) * * * * ** * - * 8 
Kalilani 2016 (20) * * * * ** * * - 8 
Kauppi, 2014 (41) - * * * ** * * - 7 
Lorefält, 2007 (16) * * * * ** * * - 8 
Melton, 2006(23) * * * * ** * * - 8 
Pouwels 2013 (24) * * * * ** * * - 8 
Schneider, 2008 (25) _ * * * ** * * - 7 
Wiklund, 2016 (42) - * * * ** * * - 7 

















Same method of 
ascertainment for 








* - * - ** * * - 6 
Grisso 1997 
(40) 
* - * - ** - * - 5 
Lau, 2001 (28) * - * - ** - * * 6 




Seventeen studies (14 cohort and 3 case-control), with a total of 2,329,424 participants, were 
included in the meta-analysis for hip fractures (Supplementary data 6). Overall, the meta-
analysis of the included studies based on the random effects model, showed that PD patients 
have an increased risk for hip fractures compared to controls (2.40, 95% CI 2.04 to 2.82; Figure 




Nine cohort studies, with a total of 1,356,711 participants, were included in the meta-analysis 
for non-vertebral fractures (Supplementary data 6). Overall, the meta-analysis of the included 
studies based on the random effects model showed that PD patients have an increased risk for 
non-vertebral fractures compared to controls (1.80, 95% CI: 1.60 to 2.01; Figure 2B). The 




Figure 2: Forest plots of the association between Parkinson’s disease (PD) and the risk of hip (A) and non-
vertebral (B) fractures. Random effects model was used to pool the overall effect size (ES) and 95% confidence 
intervals (CIs). The diamond represents the pooled ES and the squares and horizontal lines represent the ES and 
95% CI respectively for each individual study 
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Subgroup and sensitivity analyses 
Hip fractures 
Table 4 shows the effects of PD on hip fracture risk from the different subgroup analyses 
performed. Only the gender subgroup analysis suggested a significant difference between 
groups, as the confidence intervals did not overlap (Figure 3). The relative risk for hip fractures 
was higher in men (2.93, 95% CI 2.05 to 4.18) than in women (1.81, 95% CI 1.61 to 2.04). The 
difference here may be due in large part to the lower rate of fractures, and a smaller 
denominator, in men. There were no significant effects of the geographical location, use of 
specific clinical criteria for diagnosing Parkinson’s disease, study design, type of effect size 
reported (e.g. HR, RR), whether the diagnosis of Parkinson’s disease or Parkinsonism was used 
or whether self-report was the only method of identifying patients with PD.  
A sensitivity analysis was performed using the studies that scored ≥7 out of 9 stars in the 
Newcastle Ottawa Scale. Three case-control studies were removed from the analysis (28, 36, 
37, 40). The overall effect size was found to be 2.34, 95% CI: 1.98, 2.27, which was similar to 
the one calculated for all the studies (2.40, 95% CI 2.04 to 2.82).  
In order to identify possible reasons for the increased heterogeneity observed, a leave-one-out 
sensitivity analysis was performed. No single study affected the overall heterogeneity, with all 
the leave-one-out analyses having I2 values greater than 80% (data not shown).  Meta-
regression analysis suggested that gender and location, accounted for 74.1% of the variance 
between studies. 
 
Factors Number of studies Effect size (95% 
CI) 
Heterogeneity I2 
(%) between studies 
p value for 
heterogeneity 
Gender 
Male 7 (23, 27, 28, 35, 36, 38, 40) 2.93 (2.05, 4.18) 68.0 0.005 




HR 10 (21, 23-25, 27, 35, 36, 38, 41, 42) 2.50 (2.03, 3.08) 85.5 <0.001 
RR 3 (15, 16, 28) 2.92 (1.35, 6.30) 0 0.509 
OR 2 (37, 40) 3.65 (1.10, 12.18) 69.0 0.072 
IRR 2 (20, 22) 1.91 (1.26, 2.92) 78.5 0.031 
 
Study design 
Cohort 14 (15, 16, 20-25, 27, 35, 36, 38, 41, 42) 2.34 (1.98, 2.77) 89.5 <0.001 
Case-control 3 (28, 37, 40) 3.42 (1.72, 6.79) 34.1 0.208 
 
Clinical criteria reported for diagnosis of PD 
Yes a 3 (15, 16, 23) 3.00 (1.86, 4.83) 0 0.549 
No  14 (20-22, 24, 25, 27, 28, 35-38, 40-42) 2.37 (2.00, 2.79) 89.0 <0.001 
 
Diagnosis 
Parkinson's 14 (15, 16, 20-22, 24, 25, 27, 35, 37, 38, 
40-42) 
2.36 (1.98, 2.81) 89.3 <0.001 
Parkinsonism 3 (23, 28, 36) 2.46 (1.87, 3.26) 11.2 0.337 
 
Only self-report used for the definition of PD 
Yes 2 (28, 40) 2.33 (1.99, 2.74) 88.0 <0.001 
No 15 (15, 16, 20-25, 27, 35-38, 41, 42) 5.18 (2.24, 11.95) 0 0.415 
 
Study location 
Asia 3 (21, 28, 36) 2.39 (2.02, 2.82) 0 0.468 
Europe 8 (15, 16, 22, 24, 27, 37, 41, 42) 2.32 (1.87, 2.89) 92.1 <0.001 
Oceania 1 (35) 1.45 (1.14, 1.84) NA NA 
USA 5 (20, 23, 25, 38, 40) 3.03 (2.26, 4.05) 12.4 0.335 
Table 4: Summary effect sizes from the different subgroup analyses performed for the association between 
Parkinson’s disease (PD) and the risk of hip fracture. Only the effect sizes for gender did not have overlapping 
confidence intervals (shown in bold) 
a Genever et al (15): diagnosed by a consultant Care of the Elderly physician, specialised in movement disorders, 
using the United Kingdom Parkinson’s Disease Society Brain Bank criteria; Lorefält et al (16):diagnosis in 
geriatric and neurological departments, UK Parkinson's Disease Society Brain Bank criteria; Melton et al (23): 
at least two of four cardinal signs: resting tremor, bradykinesia, rigidity, or impaired postural reflexes with all 
three of the following: (1) no secondary cause; (2) no documentation of unresponsiveness to levodopa treatment 
(applicable only to treated patients); and (3) no prominent or early (within 1 year of onset) signs of more extensive 
nervous system involvement (e.g., dementia or dysautonomia) not otherwise explained 




Figure 3: Forest plots of the subgroup analysis based on gender of the association between Parkinson’s disease 
(PD) and the risk of hip fractures. Random effects model was used to pool the overall effect size (ES) and 95% 
confidence intervals (CIs). The diamond represents the pooled ES and the squares and horizontal lines represent 
the ES and 95% CI respectively for each individual study 
 
Non-vertebral fractures 
In order to perform the gender subgroup analysis, individual effect sizes from one study had to 
be calculated for the male group, as described in the methods (23). The individual effect sizes 
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for fracture sites were then pooled using random effects model to calculate the overall effect 
size by gender (Supplementary material 6). The forest plot of the gender subgroup analysis is 
shown in Figure 4. Overall, the effect size for non-vertebral fractures in male patients with PD 
(2.26, 95% CI: 1.37 to 3.73), was higher than the one in women (1.82, 95% CI: 1.33 to 2.48), 
but the confidence intervals overlapped.  
Table 5 shows the effects of PD on non-vertebral fracture risk from the different subgroup 
analyses performed. There were no significant effects of the geographical location, use of 
specific clinical criteria for diagnosing Parkinson’s disease, effect size reported by the study, 
or whether the diagnosis of Parkinson’s disease or Parkinsonism was used. No sensitivity 
analysis was performed for study quality, as all the studies included scored ≥7 out of 9 stars.  
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Figure 4: Forest plots of the subgroup analysis based on gender of the association between Parkinson’s disease 
(PD) and the risk non-vertebral fractures. Random effects model was used to pool the overall effect size (ES) and 
95% confidence intervals (CIs). The diamond represents the pooled ES and the squares and horizontal lines 
represent the ES and 95% CI respectively for each individual study 
 
 
Factors Number of studies Effect size (95% CI) Heterogeneity I2 
between studies (%) 
p value for 
heterogeneity 
Gender 
Male 2 (23, 39)  2.26 (1.37, 3.73) 0 0.838 
Female 2 (23, 25) 1.82 (1.33, 2.48) 0 0.772 
 
Effect size 
HR 5 (21, 23-25, 39) 2.03 (1.76, 2.34) 0 0.983 
RR 2 (15, 16) 1.94 (1.09, 3.45) 0 0.934 
IRR 2 (20, 22)   1.64 (1.41, 1.90) 55.0 0.136 
 
Clinical criteria reported for diagnosis of PD 
Yes a 3 (15, 16, 23) 1.89 (1.37, 2.61) 0 0.992 
No  6 (20-22, 24, 25, 39) 1.82 (1.57, 2.10) 54.1 0.053 
 
Diagnosis 
Parkinson’s 8 (15, 16, 20-22, 24, 25, 
39) 
1.80 (1.59, 2.05) 37.2 0.132 
Parkinsonism 1 (23) 1.87 (1.27, 2.76) NA NA 
 
Study location 
Asia 1 (21) 2.05 (1.71, 2.45) NA NA 
Europe 4 (15, 16, 22, 24) 1.57 (1.45, 1.71) 0 0.542 
USA 4 (20, 23, 25, 39) 1.86 (1.58, 2.19) 0 0.917 
Table 5: Summary effect sizes from the different subgroup analyses performed for the association between 
Parkinson’s disease (PD) and the risk of non-vertebral fractures 
a Genever et al (15): diagnosed by a consultant Care of the Elderly physician, specialised in movement disorders, 
using the United Kingdom Parkinson’s Disease Society Brain Bank criteria; Lorefält et al (16):diagnosis in 
geriatric and neurological departments, UK Parkinson's Disease Society Brain Bank criteria; Melton et al (23): 
at least two of four cardinal signs: resting tremor, bradykinesia, rigidity, or impaired postural reflexes with all 
three of the following: (1) no secondary cause; (2) no documentation of unresponsiveness to levodopa treatment 
(applicable only to treated patients); and (3) no prominent or early (within 1 year of onset) signs of more extensive 
nervous system involvement (e.g., dementia or dysautonomia) not otherwise explained. HR: Hazard ratio; RR: 





The funnel plot of the meta-analysis data on hip fractures was not in perfect symmetric 
distribution (Supplemental material 6). The Egger’s test suggested evidence of significant bias 
(p = 0.001). This finding should be treated cautiously, as it can probably be explained by the 
high heterogeneity observed between studies. The adjusted estimate using the trim and fill 
method was 2.26, 95% CI: 1.93 to 2.65. The non-vertebral fracture analysis had fewer than 10 
studies so a test for publication bias was not performed. 
 
Discussion  
Overall, this study showed that there is an increase in the risk of hip and non-vertebral fractures 
in patients with Parkinson’s disease. This is a clinically important increased risk of hip fracture; 
for example, the risk is similar to the increased risk of hip fracture in analyses of patients who 
ever used corticosteroids (2.07 in female and 2.62 in male) (43). This study also showed a 
higher relative risk of hip fractures in male than in female patients; in the general population, 
hip fractures are more common in female (44). The higher relative risk in men may be due in 
part to a lower rate of fractures and a smaller denominator for relative risk in men without 
Parkinson’s than women. 
The increase in the risk of fractures in patients with PD has been reported in systematic reviews 
and meta-analyses previously (5, 6, 8). Despite the differences in methodologies and scope, 
our review found similar increases in risks. Tan et al conducted a meta-analysis on the risk of 
fractures. Overall, that study showed that PD patients had an increased risk of fractures 
compared to controls (pooled HR= 2.66, 95% CI= 2.10 to 3.36), with male patients with PD 
having similar risks to female PD patients. The hip fracture subgroup analysis included four 
studies and reported an HR of 2.66 (2.07, 3.42), which was similar to our findings. The non-
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vertebral fracture subgroup analysis only included two studies, but showed, similarly to our 
report, an increased risk in PD patients, with a pooled HR= 1.61 (0.70, 3.73). (6). The Torsney 
et al review, published around the same period as the Tan et al review, also reported the risk of 
fractures in general, and did not use a site-specific approach. Their overall effect size was 2.28 
(95% CI 1.83 to 2.83) (5). The most recently published related meta-analysis focused on 
evaluating the risk for hip fractures and found an overall HR of 3.13 with 95% CI= 2.53 to 3.87 
(8). Our study selection included nine more studies (15, 16, 20, 25, 28, 35-37, 40).  
A major cause of fractures in patients with Parkinson’s disease may be their increased risk of 
multiple falls (4). There may also be a contribution from low BMD. In a cross-sectional study, 
BMD was found to be 7% lower than in controls (25). It has been shown in men that the rate 
of bone loss is three times the expected level (39). The reduction in BMD might relate to lower 
body weight; women with PD weigh on average 6 kg less than controls (25).    
Hip fractures are particularly important in patients with PD. The mortality rate of patients with 
this disorder has been reported to be doubled after a hip fracture compared with those without 
the disease (45). They also have a greater impact on the health care system, with more 
complications and longer hospital admissions (46). 
The high risk of fractures in patients with Parkinson’s disease is recognised in fracture scores 
like QFracture (47), but not in others like FRAX. The fracture risk would be better estimated 
by FRAX once it includes falls in the assessment of risk as they are an independent risk factor 
for fracture (48). The problem arises from the fact that some recommendations for the treatment 
of osteoporosis use score outcomes to assess the initiation of treatment to reduce fractures (49). 
This results in a small percentage of patients with PD receiving treatments for osteoporosis. A 
recent study showed that only 40% of the PD patients diagnosed with fragility fractures were 
receiving evidence-based treatment for osteoporosis and not all of them were assessed by 
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physiotherapists (50).  PD available guidelines do not address the issue of bone health in detail 
(51-53). PD-specific algorithms for the assessment and management of bone health have been 
suggested in some studies, but national and international guidelines also have to be revised. 
Fracture risk assessment and evidence based treatment for osteoporosis should be part of the 
care in patients with PD (54). Clinical trial evidence is also needed to check whether anti-
osteoporotic treatment given on top of falls prevention strategies would further reduce the risk 
of fractures in this group of patients. One trial to address this issue is underway 
(ClinicalTrials.gov Identifier: NCT03924414). 
There were several limitations in our study. First, we only included studies published in English 
language, thus data from specific geographic areas might have been missed.  The majority of 
the published studies have data from white/Caucasian population and were mainly oriented in 
Europe and the USA; therefore, this might have affected the results. The diagnosis of 
Parkinson’s disease was not necessarily performed by a neurologist. This might have resulted 
in misclassification of the diagnosis in some patients. If patients diagnosed with PD did not 
actually have the disorder, then the analysis would only lead to an underestimation of the risk 
of fractures. Our study also assumed that the risk of fractures in patients with Parkinsonism 
and Parkinson’s disease was similar and included all the studies in the overall analysis. The 
subgroup analysis supported our assumption, as there was no difference in the risks between 
the two groups. Significant heterogeneity was also an issue in this study. The random effects 
model allows for heterogeneity, so using this model gives a quantified result. Moreover, 
different sensitivity analyses were performed to identify possible reasons for this heterogeneity.  
The meta-regression analysis suggested that gender and location, accounted for 74.1% of the 
variance between studies. The heterogeneity was also probably the cause for the funnel plot 
asymmetry observed, as the number of studies was not substantially more than 10 (32). 
Although it would be interesting to check the effect on BMD and falls on the effect size, not 
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many studies included BMD and falls data. The effect of PD medication would also be an 
interesting subgroup analysis, but it was not included in our priori analyses, so the data were 
not extracted.  
This comprehensive systematic review and meta-analysis demonstrates a strong association 
between Parkinson’s disease and risk of hip and non-vertebral fractures. Patients with PD 
should have fracture risk assessment in their standard care. 
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